ArticleAvicenna journal of medical biotechnology
Altered miR-223 Expression in Sputum for Diagnosis of Non-Small Cell Lung Cancer.
Article in Avicenna journal of medical biotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- High diagnostic value of miRNAs for NSCLC: quantitative analysis for both single and combined miRNAs in lung cancer.Annals of medicine · 2021Pooled it
- Diagnostic and Prognostic Role of miR-192 in Different Cancers: A Systematic Review and Meta-Analysis.BioMed research international · 2021Pooled it
- MicroRNAs in sputum specimen as noninvasive biomarkers for the diagnosis of nonsmall cell lung cancer: An updated meta-analysis.Medicine · 2019Pooled it
- Sputum Liquid Biopsy for Lung Cancer Screening, Diagnosis, Subtyping, Surveillance, Response Prediction, and Prognostication: A Scoping Review.Medical sciences (Basel, Switzerland) · 2026Article
- Small nucleolar RNA dysregulation and potential roles in bovine subclinical mastitis.Journal of animal science and biotechnology · 2025Article
- MicroRNA155 in non-small cell lung cancer: a potential therapeutic target.Frontiers in oncology · 2025Review
- Caveolin and NOS in the Development of Muscular Dystrophy.International journal of molecular sciences · 2024Review
- MiR-223-3p in Cancer Development and Cancer Drug Resistance: Same Coin, Different Faces.International journal of molecular sciences · 2024Review
- Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics.Genes & diseases · 2023Review
- MiR-212 value in prognosis and diagnosis of cancer and its association with patient characteristics: a systematic review and meta-analysis.Cancer cell international · 2022Review
- Circulatory microRNAs in helminthiases: Potent as diagnostics biomarker, its potential role and limitations.Frontiers in veterinary science · 2022Review
- Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy.Cancer research · 2021Article
- PDS5A and PDS5B in Cohesin Function and Human Disease.International journal of molecular sciences · 2021Review
- Poorly Differentiated Neuroendocrine Larynx Carcinoma: Clinical Features and miRNAs Signature-A New Goal for Early Diagnosis and Therapy?Journal of clinical medicine · 2021Article
- The Role of Liquid Biopsy in Early Diagnosis of Lung Cancer.Frontiers in oncology · 2021Review
- MicroRNA-155 from sputum as noninvasive biomarker for diagnosis of active pulmonary tuberculosis.Iranian journal of basic medical sciences · 2020Article
- Ultrasound-targeted microbubble destruction-mediated miR-767 inhibition suppresses tumor progression of non-small cell lung cancer.Experimental and therapeutic medicine · 2020Article
- miR-3074-3p promotes myoblast differentiation by targeting Cav1.BMB reports · 2020Article
- Low serum miR-223 expression predicts poor outcome in patients with acute myeloid leukemia.Journal of clinical laboratory analysis · 2020Article
- MicroRNA-based biomarkers for diagnosis of non-small cell lung cancer (NSCLC).Thoracic cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiagnosis of Non-small Cell Lung Cancer (NSCLC) at an early stage is a daunting challenge due to the deficiency of specific noninvasive markers. MicroRNAs (miRNAs) play important roles in the initiation and progression of NSCLC. Measuring miRNA expression levels could provide a potential approach for the diagnosis of NSCLC. Our goals were to examine miR-223, miR-212, miR-192, miR-3074, SNORD33 and SNORD37 expression levels in tissue and sputum of NSCLC patients and cancer free subjects for molecular diagnosis of NSCLC.
methodsRelative expressions of miR-223, miR-212, miR-192, miR-3074, SNORD33 and SNORD37 were examined with quantitative real-time RT-PCR assay in tissue and sputum obtained from 17 NSCLC patients and 17 controls.
resultsmiR-3074 was upregulated in tissue samples of NSCLC patients compared with control group. miR-223 was upregulated, miR-212 and SNORD37 were downergulated in sputum samples of patients compared with controls. miR-223 quantification produced 82% sensitivity and 95% specificity with areas under the ROC curve at 0.90 in detection of NSCLC.
conclusionmiR-223 clearly discriminated cancer patients from cancer-free subjects and our results suggest that miR-223 could be a diagnostic useful biomarker. The measurement of altered miRNA expression in sputum samples manifested the potential noninvasive approach for detection of lung cancer.
Indexed as
Identifiers
29090068PMC5650736W2760261699What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.